{"id":"actemra-mtx","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Infection (including serious infections)"},{"rate":"10-15","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"10-15","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL2074706","moleculeType":"Small molecule","molecularWeight":"466.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling which is a key driver of inflammation in rheumatoid arthritis. By blocking this pathway, it reduces production of inflammatory cytokines and adhesion molecules. The combination with methotrexate enhances efficacy through complementary immunosuppressive mechanisms.","oneSentence":"Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses, used in combination with methotrexate (MTX) for rheumatoid arthritis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:05.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe, in combination with methotrexate)"}]},"trialDetails":[{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT03737708","phase":"PHASE4","title":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2019-02-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":21},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT03301883","phase":"PHASE4","title":"A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-26","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT06048224","phase":"PHASE3","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2020-12-28","conditions":"Moderate to Severe Active Rheumatoid Arthritis","enrollment":669},{"nctId":"NCT03699631","phase":"PHASE2","title":"PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-11-06","conditions":"Hematologic Malignancy","enrollment":29},{"nctId":"NCT02206035","phase":"PHASE2","title":"A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant","status":"COMPLETED","sponsor":"William R. Drobyski, MD","startDate":"2014-12","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":45},{"nctId":"NCT04688021","phase":"PHASE2","title":"A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.","status":"UNKNOWN","sponsor":"Yi Luo","startDate":"2020-12-03","conditions":"Leukemia, Graft-versus-host-disease","enrollment":46},{"nctId":"NCT05090410","phase":"PHASE3","title":"Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Atsushi Kawakami","startDate":"2021-03-03","conditions":"Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor","enrollment":400},{"nctId":"NCT02659150","phase":"PHASE4","title":"Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2016-05-18","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT04157010","phase":"PHASE4","title":"Tocilizumab REMission in Early RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT02569736","phase":"","title":"Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation","status":"COMPLETED","sponsor":"Association Aquitaine de Recherche Clinique en Rhumatologie","startDate":"2014-09","conditions":"Arthritis, Rheumatoid, Tocilizumab, T-Lymphocytes, Helper-Inducer","enrollment":60},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT00535782","phase":"PHASE3","title":"A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10-31","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT01007435","phase":"PHASE3","title":"A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Rheumatoid Arthritis","enrollment":1162},{"nctId":"NCT01878318","phase":"PHASE4","title":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT02837146","phase":"PHASE3","title":"Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Maria Stoenoiu","startDate":"2015-12","conditions":"Rheumatoid Arthritis","enrollment":45},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01587989","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT01399697","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":261},{"nctId":"NCT01254331","phase":"PHASE3","title":"An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":51},{"nctId":"NCT01120366","phase":"PHASE4","title":"Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation","status":"COMPLETED","sponsor":"SURPRISE Study Group","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":233},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT01353859","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT00106535","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Rheumatoid Arthritis","enrollment":1196},{"nctId":"NCT01245452","phase":"NA","title":"Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate","status":"COMPLETED","sponsor":"Patrick Durez","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT01347983","phase":"PHASE3","title":"Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Chugai Pharma Taiwan","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT01258712","phase":"PHASE3","title":"Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Chugai Pharma Taiwan","startDate":"2010-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":86},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00144521","phase":"PHASE3","title":"Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2004-02","conditions":"Rheumatoid Arthritis","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":303,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Actemra +MTX","genericName":"Actemra +MTX","companyName":"Zhejiang Hisun Pharmaceutical Co. Ltd.","companyId":"zhejiang-hisun-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses, used in combination with methotrexate (MTX) for rheumatoid arthritis. Used for Rheumatoid arthritis (moderate to severe, in combination with methotrexate).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}